Detailed Information on Publication Record
2005
The long-lasting improvement of sexual dysfunction in patients with advanced, fluctuating Parkinson's disease induced by pergolide: Results of an open, prospective, six months and one-year follow-up
POHANKA, Michal, Petr KAŇOVSKÝ, Martin BAREŠ, Jiří PULKRÁBEK, Ivan REKTOR et. al.Basic information
Original name
The long-lasting improvement of sexual dysfunction in patients with advanced, fluctuating Parkinson's disease induced by pergolide: Results of an open, prospective, six months and one-year follow-up
Name in Czech
Dlouhodobé zlepšení sexuální dysfunkce podáváním pergolidu u pacientů v pokročilém stadiu Parkinsovony nemoci- prospektivní 6 měsíční sledování
Authors
POHANKA, Michal (203 Czech Republic), Petr KAŇOVSKÝ (203 Czech Republic, guarantor), Martin BAREŠ (203 Czech Republic), Jiří PULKRÁBEK (203 Czech Republic) and Ivan REKTOR (203 Czech Republic)
Edition
Česká a slovenská neurologie a neurochirurgie, Česká lékařská společnost J.E.Purkyně, 2005, 1210-7859
Other information
Language
English
Type of outcome
Článek v odborném periodiku
Field of Study
30000 3. Medical and Health Sciences
Country of publisher
Czech Republic
Confidentiality degree
není předmětem státního či obchodního tajemství
Impact factor
Impact factor: 0.070
RIV identification code
RIV/00216224:14110/05:00031906
Organization unit
Faculty of Medicine
UT WoS
000233791000006
Keywords in English
Pergolid; Parkinson disease; treatment; sexual dysfunction
Tags
International impact, Reviewed
Změněno: 31/3/2010 23:31, prof. MUDr. Martin Bareš, Ph.D.
V originále
The presented study aimed to assess whether the latter effect of pergolide in advanced Parkinson's disease remains stable also in the longer time period. Fourteen male patients suffering from Parkinson's disease, each of whom had been treated with L-DOPA, and in whom additional treatment with peroral dopaminergic agonist (DA) was needed, were followed for a six-months and twelve-months period. Pergolide mesylate (Permax (R)) was given to each patient, and titrated to a total daily dose of 3 mg. All of the patients were taking L-DOPA. There were statistically significant differences between the values of UPDRS III motor subscale, UPDRS IV (complications of therapy) subscale and all subscales of IIEF when months 0 and 1 were compared with the results obtained at months 3, 6 and 12. Pergolide mesylate, when added to L-DOPA, significantly improved sexual functions in younger male patients who were still interested in sexual activities in all aspects.
In Czech
Dlouhodobé zlepšení sexuální dysfunkce podáváním pergolidu u pacientů v pokročilém stadiu Parkinsovony nemoci- prospektivní 6 měsíční sledování
Links
MSM0021622404, plan (intention) |
|